Annexon, Inc. (NASDAQ:ANNX) Stock Holdings Raised by Fmr LLC

Fmr LLC lifted its stake in shares of Annexon, Inc. (NASDAQ:ANNX) by 3.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,561,949 shares of the company’s stock after purchasing an additional 262,229 shares during the period. Fmr LLC owned about 8.10% of Annexon worth $50,687,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Sandia Investment Management LP acquired a new stake in Annexon during the second quarter valued at approximately $49,000. Victory Capital Management Inc. bought a new stake in shares of Annexon in the 2nd quarter valued at approximately $51,000. Principal Financial Group Inc. acquired a new stake in shares of Annexon during the 2nd quarter valued at approximately $56,000. Comerica Bank bought a new position in Annexon during the first quarter worth $72,000. Finally, Allegheny Financial Group LTD boosted its holdings in Annexon by 16.1% in the second quarter. Allegheny Financial Group LTD now owns 25,200 shares of the company’s stock worth $123,000 after purchasing an additional 3,500 shares during the period.

Insider Buying and Selling at Annexon

In other news, EVP Ted Yednock sold 5,408 shares of Annexon stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $7.41, for a total transaction of $40,073.28. Following the sale, the executive vice president now owns 71,365 shares of the company’s stock, valued at approximately $528,814.65. The trade was a 7.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 12.67% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ANNX shares. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Annexon in a report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Annexon Stock Performance

Annexon stock opened at $5.10 on Friday. Annexon, Inc. has a one year low of $2.27 and a one year high of $8.40. The company has a 50-day simple moving average of $6.50 and a 200-day simple moving average of $5.98. The firm has a market capitalization of $543.61 million, a P/E ratio of -4.86 and a beta of 1.10.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.